Holen Sie sich die Stockscreener-App
3.50
1.34%
0.02
Schlusskurs vom Vortag:
$3.48
Offen:
$3.46
24-Stunden-Volumen:
74,216
Relative Volume:
0.31
Marktkapitalisierung:
$139.31M
Einnahmen:
$2.70M
Nettoeinkommen (Verlust:
$5.53M
KGV:
31.82
EPS:
0.11
Netto-Cashflow:
$-10.55M
1W Leistung:
+2.52%
1M Leistung:
+19.55%
6M Leistung:
+59.58%
1J Leistung:
+56.74%
1-Tages-Spanne:
$3.46
$3.59
1-Wochen-Bereich:
$3.31
$3.60
52-Wochen-Spanne:
$1.82
$3.71
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Vergleichen Sie ORMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.50 | 138.51M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
757.02 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.72 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.92 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.98 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Jobs Data: Is Oramed Pharmaceuticals Inc stock good for income investors2025 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Oramed Shares Face Pressure Amid Strategic Pivot and Dividend Focus - AD HOC NEWS
Oramed Pharm completes warrant sale, boosting liquidity - MSN
Is Oramed Pharmaceuticals Inc. stock undervalued right nowVolume Analysis Techniques & Plan Every Trade With Controlled Risk - bollywoodhelpline.com
What hedge funds are buying Oramed Pharmaceuticals Inc.Recession Risk & Daily Technical Forecast Reports - bollywoodhelpline.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest - MarketBeat
Published on: 2026-01-17 10:34:33 - baoquankhu1.vn
Oramed Pharmaceuticals Inc.: - marketscreener.com
Oramed Pharm pivots with Lifeward strategic platform deal - TipRanks
Oramed Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Oramed to transfer oral drug delivery platform to Lifeward By Investing.com - Investing.com Nigeria
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal - Investing.com Nigeria
Buyout Rumor: Can Oramed Pharmaceuticals Inc maintain sales growthQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Oramed And Lifeward Reveal Strategic Deal - Pulse 2.0
Oramed to transfer oral drug delivery platform to Lifeward - Investing.com India
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal By Investing.com - Investing.com South Africa
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - manilatimes.net
Oramed and Lifeward Announce Strategic Transaction - Nasdaq
Upcoming Events - FinancialContent
Lifeward Ltd. announced that it expects to receive $20 million in funding from Oramed Pharmaceuticals Inc. - marketscreener.com
Oramed Announces Shareholder Capital Return Following Strategic Windfall - AD HOC NEWS
Take Profit: Will Oramed Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Intraday Action & Growth Focused Investment Plans - Улправда
Why Oramed Pharmaceuticals Inc. stock could outperform in 2025Trade Performance Summary & Risk Managed Investment Entry Signals - Улправда
Is Oramed Pharmaceuticals Inc. stock a buy in volatile markets2025 Retail Activity & Daily Volume Surge Signals - ulpravda.ru
Will Oramed Pharmaceuticals Inc. stock outperform value stocks2025 Key Lessons & Intraday High Probability Alerts - ulpravda.ru
Oramed Pharmaceuticals Inc. Declares Dividend of $0.25 (NASDAQ:ORMP) - MarketBeat
Oramed inks deal with Medicox for oral insulin in South Korea - The Pharma Letter
Is Oramed Pharmaceuticals Inc. (OJU1) stock suitable for passive index fundsMarket Sentiment Shifts & Outstanding Capital Returns - Улправда
MSN Money - MSN
Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026 - MarketScreener
Oramed stock rises after receiving $18 million payment from Scilex By Investing.com - Investing.com Nigeria
Oramed receives $18 million payment from Scilex, declares dividend By Investing.com - Investing.com Nigeria
Oramed Pharm Announces Dividend After Scilex Payment Gain - TipRanks
Oramed receives $18 million payment from Scilex, declares dividend - Investing.com
Oramed Pharmaceuticals Inc Receives $18 Million Payment and Approves Dividend - TradingView
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - Barchart.com
What analysts say about Oramed Pharmaceuticals Inc stockLow Beta Stocks & Breakthrough Profit Margins - earlytimes.in
Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation - TipRanks
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years - Investing.com
Oramed Pharmaceuticals completes $28.5 million warrant repurchase by Scilex - Investing.com Nigeria
Oramed Pharm Completes Warrant Sale, Boosting Liquidity - TipRanks
Oramed Pharmaceuticals Completes Warrant Repurchase with Scilex - TradingView — Track All Markets
Scilex Holding completes $27 million repurchase of warrants from Oramed By Investing.com - Investing.com South Africa
Scilex Holding completes $27 million repurchase of warrants from Oramed - Investing.com
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
3.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):